Posttransplantation lymphoproliferative disorder (PTLD) in liver and small bowel transplant recipients

Post-Transplant Lymphoproliferative Disorders

Volumn , Issue , 2010, Pages 153-162

  Pineda, Jaime ^a   Mazariegos, George V ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84890192070     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-01653-0_12     Document Type: Chapter

References (37)

1. Avolio A, Agnes S, Barbarino R, et al. Post transplant lymphoproliferative disorder after liver transplantation: analysis of early and late cases in a 255 patient series. Transplant Proc. 2007;39:1956
2. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet. 1984;1(8377):583-7
3. Paya C, Fung J, Nalesnik M, et al. Epstein-Barr virus-induced post transplant lymphoproliferative disorder. ASTS/ASTP EBV-PTLD task force and the mayo clinic organized international consensus development meeting. Transplantation. 1999;68:1517
4. D'Alessandro A, Knechtle S, Thomas Chin L, et al. Liver transplantation in pediatric patients: twenty years of experience at the University of Wisconsin. Pediatr Transplant. 2007;11:661
5. Jain A, Mazariegos G, Kashyap R, et al. Pediatric liver transplantation. Transplantation. 2002;73:941-7
6. Jain A, Nalesnik M, Reyes J, et al. Post transplant lymphoproliferative disorder in liver transplantation a 20-years experience. Ann Surg. 2002;236(4):429-37
7. Kremers WK, Devarbhavi HC, Wiesner RH, et al. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant. 2006;6(5 Pt 1):1017-24
8. McDiarmid SV, Jordan S, Lee G, et al. Prevention and preemptive therapy of post transplant lymphoproliferative disease in pediatric liver recipients. Transplantation. 1991;66(12):1604-11
9. Lee T, Savoldo B, Rooney C, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant. 2005;5:2222-8
10. Ganschow R, Grabhorn E, Schultz A, et al. Long-term results of basiliximab induction immunosuppression in pediatric liver transplant recipients. Pediatr Transplant. 2005;9(6):741-5
11. Cacciarelli TV, Reyes J, Jaffe R, et al. Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients. Pediatr Transplant. 2001;5:359-64
12. Guthery S, Heubi J, Bucuvalas J, et al. Determination of risk factors for Epstein-Barr virus associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Transplantation. 2003;75:987-93
13. Allen U, Farkas G, Hebert D, et al. Risk factors for post-transplant lymphoproliferative disorder in pediatric patients: a case-control study. Pediatr Transplant. 2005;9:450-5
14. McLaughlin K, Wajstaub S, Marotta P, et al. Increased risk for posttransplant lymphoproliferative disease in recipients of liver transplants with hepatitis C. Liver Transplant. 2000;6:570-4
15. Fyle A, Vilmer E. Post-transplant lymphoproliferative disorder in children. Incidence, prognosis and treatment options. Pediatr Drug. 2005;7:55-65
16. Patel H, Vogl D, Aqui N, et al. Post transplant lymphoproliferative disorder in adult liver transplant recipients: a report of seventeen cases. Leuk Lymphoma. 2007;48:885-91
17. Hurwitz M, Desai DM, Cox KL, et al. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation. Pediatr Transplant. 2004;8:267-72
18. Mazariegos G. Withdrawal of immunosuppression in liver transplantation: lessons learned from PTLD. Pediatr Transplant. 2004;8:210-3
19. Mazariegos G, Sindhi R, Angus T, et al. Clinical tolerance following liver transplantation: long term results and future prospects. Transpl Immunol. 2007;17:114-9
20. Aucejo F, Profile G, Miller C. Who is at risk for post-transplant lymphoproliferative disorders (PTLD) after liver transplantation J Hepatol. 2006;44:19-23
21. Hayashida M, Ogita K, Matsuura T, et al. Successful prolonged rituximab treatment for posttransplant lymphoproliferative disorder following living donor liver transplantation in a child. Pediatr Transplant. 2007;11:671-5
22. Jain A, Marcos A, Pokharma R, et al. Rituximab (Chimeric Anti-CD20 Antibody) for post transplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center. Transplantation. 2005;80:1692-8
23. Dufour J, Fey M. What is the current treatment of PTLD after liver transplantation J Hepatol. 2006;44:23-6
24. Smets F, Vajro P, Cornu G, et al. Indications and results of chemotherapy in children with post transplant lymphoproliferative disease after liver transplantation. Transplantation. 2000;69 (5):982-5
25. Gross TG, Hinrichs SH, Winner J, et al. Treatment of post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation with low-dose chemotherapy. Ann Oncol. 1998;9:339-40
26. American Gastroenterological Association (AGA). American Gastroenterological Association medical position statement: short bowel syndrome and intestinal transplantation. Gastroenteroly. 2003;124:1105-10
27. Quintini C, Kato T, Gaynor JJ et al. Analysis of Risk factors for the development of posttransplant lymphoproliferative disorder among 119 children who received primary intestinal transplant at a single center. Transplant Proc. 2006;38:1755-8
28. Abu-Elmagd K, Reyes J, Bond G, et al. Clinical intestinal transplantation: a decade of experience at single center. Ann Surg. 2001;234(3):404-17
29. Bond G, Felmet K, Jafee R et al. Intestinal and multiviceral transplantation. In: Rogers ND, editor. Textbook of pediatric care. Philadelphia, PA: Lippincott Williams & Wilkins; 2008. p.1550-61
30. Bond G, Mazariegos G, Sindhi R, et al. Evolutionary experience with inmunosuppression in pediatric intestinal transplantation. J Pediatr Surg. 2005;40:274-80
31. Pascher A, Kohler S, Neuhaus P et al. Present status and future perspectives of intestinal transplantation. Transpl Int. 2008;21:401-14
32. Green M, Bueno J, Rowe D, et al. Predictive negative value of persistent low Epstein-Barr virus load after intestinal transplantation in children. Transplantation. 2000;70:593-6
33. Green M, Soltys K, Rowe DT, et al. Chronic high load Epstein-Barr viral load carriage in pediatric liver transplant recipients. Pediatr Transplant. 2008;13:319-23
34. Sarkar S, Selvaggi G, Mittal N, et al. Gastrointestinal tract ulcers in pediatric intestinal transplantation patients: etiology and management. Pediatr Transplant. 2006;10:162-16
35. Sigurdsson L, Reyes J, Kocoshis SA, et al. Bacteremia after intestinal transplantation in children correlates temporally with rejection or gastrointestinal lymphoproliferative disease. Transplantation. 2000;70(2):302-35
36. Berney T, Delis S, Kato T, et al. Successful treatment of poattransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients. Transplantation. 2002;74:1000-6
37. Codeluppi M, Cocchi S, Guaraldi G, et al. Rituximab as treatment of posttransplant lymphoproliferative disorder in patients who underwent small bowel/multivisceral transplantation: report of three cases. Transplant Proc. 2005;37:2634-5